Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 3
1995 1
1996 1
1997 1
1999 1
2000 1
2001 2
2002 3
2003 2
2004 1
2005 1
2006 1
2009 4
2010 6
2011 4
2012 11
2013 8
2014 3
2015 1
2016 6
2017 3
2018 1
2021 2
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

67 results
Results by year
Filters applied: . Clear all
Page 1
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.
Etxeberria I, Bolaños E, Teijeira A, Garasa S, Yanguas A, Azpilikueta A, Kavanaugh WM, Vasiljeva O, Belvin M, Howng B, Irving B, Tipton K, West J, Mei L, Korman AJ, Sega E, Olivera I, Cirella A, Ochoa MC, Rodriguez ME, Melero A, Sanmamed MF, Engelhardt JJ, Melero I. Etxeberria I, et al. Among authors: belvin m. Proc Natl Acad Sci U S A. 2021 Jun 29;118(26):e2025930118. doi: 10.1073/pnas.2025930118. Proc Natl Acad Sci U S A. 2021. PMID: 34172583 Free PMC article.
p21-activated kinase 1: PAK'ed with potential.
Ong CC, Jubb AM, Zhou W, Haverty PM, Harris AL, Belvin M, Friedman LS, Koeppen H, Hoeflich KP. Ong CC, et al. Among authors: belvin m. Oncotarget. 2011 Jun;2(6):491-6. doi: 10.18632/oncotarget.271. Oncotarget. 2011. PMID: 21653999 Free PMC article. Review.
Is all cancer therapy immunotherapy?
Belvin M, Mellman I. Belvin M, et al. Sci Transl Med. 2015 Nov 25;7(315):315fs48. doi: 10.1126/scitranslmed.aad7661. Sci Transl Med. 2015. PMID: 26606965
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents.
Assi HH, Wong C, Tipton KA, Mei L, Wong K, Razo J, Chan C, Howng B, Sagert J, Krimm M, Diep L, Jang A, Nguyen MT, Lapuyade N, Singson V, Villanueva R, Paidhungat M, Liu S, Rangan V, Vasiljeva O, West JW, Richardson JH, Irving B, Daniel D, Belvin M, Kavanaugh WM. Assi HH, et al. Among authors: belvin m. Cancer Immunol Res. 2021 Dec;9(12):1451-1464. doi: 10.1158/2326-6066.CIR-21-0031. Epub 2021 Oct 11. Cancer Immunol Res. 2021. PMID: 34635485
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.
Singh S, Serwer L, DuPage A, Elkins K, Chauhan N, Ravn M, Buchanan F, Wang L, Krimm M, Wong K, Sagert J, Tipton K, Moore SJ, Huang Y, Jang A, Ureno E, Miller A, Patrick S, Duvur S, Liu S, Vasiljeva O, Li Y, Henriques T, Badagnani I, Jeffries S, Schleyer S, Leanna R, Krebber C, Viswanathan S, Desnoyers L, Terrett J, Belvin M, Morgan-Lappe S, Kavanaugh WM, Richardson J. Singh S, et al. Among authors: belvin m. Mol Cancer Ther. 2022 Aug 2;21(8):1326-1336. doi: 10.1158/1535-7163.MCT-21-0193. Mol Cancer Ther. 2022. PMID: 35666803
Quantitative phosphoproteomic analysis of the PI3K-regulated signaling network.
Gnad F, Wallin J, Edgar K, Doll S, Arnott D, Robillard L, Kirkpatrick DS, Stokes MP, Vijapurkar U, Hatzivassiliou G, Friedman LS, Belvin M. Gnad F, et al. Among authors: belvin m. Proteomics. 2016 Jul;16(14):1992-7. doi: 10.1002/pmic.201600118. Epub 2016 Jul 8. Proteomics. 2016. PMID: 27282143
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.
Merchant M, Moffat J, Schaefer G, Chan J, Wang X, Orr C, Cheng J, Hunsaker T, Shao L, Wang SJ, Wagle MC, Lin E, Haverty PM, Shahidi-Latham S, Ngu H, Solon M, Eastham-Anderson J, Koeppen H, Huang SA, Schwarz J, Belvin M, Kirouac D, Junttila MR. Merchant M, et al. Among authors: belvin m. PLoS One. 2018 Jan 25;13(1):e0192059. doi: 10.1371/journal.pone.0192059. eCollection 2018. PLoS One. 2018. PMID: 29370292 Free PMC article.
67 results